Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relative Bioavailability of an Investigational Single Dose of Dulaglutide After Subcutaneous Administration by a Single Dose Pen Compared to a Prefilled Syringe in Healthy Subjects

NCT03363906 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03363906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03363906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relative Bioavailability of an Investigational Single Dose of Dulaglutide After Subcutaneous Administration by a Single Dose Pen Compared to a Prefilled Syringe in Healthy Subjects
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
December 7, 2017
Completion date
June 6, 2018
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy